CR Sincock II

CR Sincock II

Director

  • Bio
    C.R. is the founder and managing partner of Transhuman Capital, a family office venture capital fund focused on early stage biotechnology companies.  Transhuman Capital was formed in 2014 when he made the fund's first investment into the seed round of Roivant Sciences, a position that he added to in several follow-on rounds.  In 2019 C.R. was the founding investor in Kriya Therapeutics, leading the seed round; the fund has subsequently participated in each follow-on round as well. In 2021, he was a founding investor in Dvant Pharma, a small molecule oncology company with IP licensed from the University of Michigan.  C.R. sits on the board of directors at Kriya and Dvant, in addition to sitting on the investment advisory board at the University of Michigan Biomedical Venture Fund. Outside of biotechnology, C.R. has been a longtime entrepreneur and investor in the aviation and energy sectors.  He is the CEO of Avflight Corporation and the EVP of Avfuel Corporation.  He started his investing career out of college at QVT Financial, a multi-strategy hedge fund based in New York.  C.R. graduated magna cum laude and phi beta kappa from Harvard College with a degree in economics and was a Baker Scholar at Harvard Business School where he earned his MBA.  He is currently a degree candidate in the Masters of Science in Biotechnology program at Johns’s Hopkins University.